Dr Rachel Dalthorp Details Her Approach to Closing Gaps in Postpartum Mental Health Care

AJMC July 21, 2024
Giuliana Grossi

Screening for postpartum depression while patients are pregnant is a crucial step to ensuring they get access to treatment if they need it postpartum, according to Rachel Dalthorp, MD, of LifeStance Health.

Rachel Dalthorp, MD, executive medical director of specialty services, LifeStance Health, discusses how the barriers to care for postpartum depression (PPD) can be addressed now that zuranolone (Zurzuvae; Sage Therapeutics/Biogen), the first oral FDA-approved treatment for PPD, has been on the market for months.

This transcript has been lightly edited for clarity.

Transcript

What have you noticed in relation to the trends of patients seeking and accessing care for postpartum depression?

We have a big problem: for every 20 moms with PPD, only 1 is going to be...